The head and neck cancer market is expected to show positive growth, mainly attributed to the increasing incident cases and the launch of upcoming therapies during the forecast period. Moreover, the advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more drug development. 

LAS VEGAS, Sept. 27, 2022 /PRNewswire/ -- DelveInsight's Head and Neck Cancer Market Insights report includes a comprehensive understanding of current treatment practices, head and neck cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Takeaways from the Head and Neck Cancer Market Report

• As per DelveInsight analysis, the head and neck cancer market size in the 7MM was approximately USD 2.9 billion in 2021.
• As per the estimates, the total head and neck cancer incident cases in the 7MM were approximately 158K in 2021. 
• Leading head and neck cancer companies such as CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC, Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La Roche, Eli Lilly and Company, and others are developing novel head and neck cancer drugs that can be available in the head and neck cancer market in the upcoming years.
• The head and neck cancer therapies in the pipeline include Leukocyte Interleukin (MULTIKINE), Toripalimab, Cabozantinib, Eftilagimod alpha (Efti/IMP321), LN-145 (Tumor Infiltrating Lymphocytes), Tislelizumab, Penpulimab/AK105, Tipifarnib, XEVINAPANT (Debio 1143), TECENTRIQ (atezolizumab), Cyramza (ramucirumab), and others.
• The head and neck cancer market is expected to grow due to factors such as an increase in the patient pool and the expected entry of emerging therapies.

Discover which therapies are expected to grab the major head and neck cancer market share @Head and Neck Cancer Market Report

Head and Neck Cancer Overview

Head and neck cancer (HNC) usually begins in the squamous cells – also known as squamous cell carcinomas of the head and neck – that line the mucosal surfaces of the head and neck (for example, those inside the mouth, throat, and voice box), but it can also begin in the salivary glands, sinuses, muscles, or nerves. Alcohol and tobacco use are the two most important risk factors for head and neck causes. 

Head and neck cancer symptoms include a lump in the neck or a sore in the mouth or throat that does not heal, a persistent sore throat, difficulty swallowing, and a change or hoarseness in the voice; however, these head and neck cancer symptoms can also be caused by other, less serious illnesses.

Physical examination/blood and urine tests, endoscopy, biopsy, biomarker testing of the tumor, X-ray/barium swallow, panoramic radiograph, ultrasound, magnetic resonance imaging, bone scan, and other tests are used for head and neck diagnosis.

Head and Neck Cancer Epidemiology Segmentation

DelveInsight estimates that there were approximately 158K incident cases of head and neck cancer in the 7MM in 2021.

Among the EU5 countries, Germany had the highest number of head and neck cancer incident cases in 2021.

The head and neck cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Incident Cases of Head and Neck Cancer
• HPV-specific Incident Cases of Head and Neck Cancer
• Site-specific Incident Cases of Head and Neck Cancer
• Molecular Alteration-specific Incident Cases of Head and Neck Cancer
• Stage-specific Incident Cases of Head and Neck Cancer

Download the report to understand which factors are driving head and neck cancer epidemiology trends @Head and Neck Cancer Epidemiological Insights

Head and Neck Cancer Treatment Market 

Chemotherapy has widely used in all lines of head and neck treatment among all available therapeutic options. Numerous drugs have been identified with the advancement of medical technologies and increased research and development activities. Immunotherapeutic options for treating HNC patients have also been identified.

Overall, head and neck cancer treatment options for patients with HNC include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Pharmacological therapies are primarily used to destroy cancer cells and are administered systematically or locally (by a medical oncologist). Chemotherapy, targeted therapy, and immunotherapy are some of the pharmacological head and neck cancer treatments available to HNC patients.

Across all countries, the most common first-line systemic therapy regimens were platinum-based combinations, such as platinum + 5-F, cetuximab + platinum 5-FU, or taxane + platinum 5-FU. However, the use of different platinum-based combinations varied significantly across countries; administration of cetuximab + platinum 5-FU was common in Italy, Germany, and Spain. In the United Kingdom, platinum with 5-FU was the most commonly used first-line regimen.

To know more about head and neck cancer treatment options, visit @New Treatment for Head and Neck Cancer 

Head and Neck Cancer Pipeline Therapies and Key Companies

• Leukocyte Interleukin (MULTIKINE): CEL-SCI
• Toripalimab: Junshi Biosciences/Coherus
• Cabozantinib: Exelixis
• Eftilagimod alpha (Efti/IMP321): Immutep S.A.S./Merck Sharp & Dohme LLC
• LN-145 (Tumor Infiltrating Lymphocytes): Iovance Biotherapeutics
• Tislelizumab: BeiGene
• Penpulimab/AK105: Akeso/Chia Tai-Tianqing
• Tipifarnib: Kura Oncology
• XEVINAPANT (Debio 1143): Merck KGaA
• TECENTRIQ (atezolizumab): Hoffmann-La Roche
• Cyramza (ramucirumab): Eli Lilly and Company

Learn more about the head and neck cancer treatment guidelines @Drugs for Head and Neck Cancer Treatment 

Head and Neck Cancer Market Dynamics

The survival of head and neck cancer is steadily improving, and it is emphasized that a better understanding of tumor pathobiology will lead to better therapies and outcomes in the head and cancer market. Clinical trials are being conducted to understand better the role of HPV and the combinations of various therapies. Response rates are higher when chemotherapy is combined with PD-1 inhibitors in HPV+ tumors. These kinds of new insights will undoubtedly be useful in the future for the growth of the head and neck cancer market.

Due to a lack of randomized neoadjuvant trials, an investigation into using newer and more active systemic regimens in the neoadjuvant setting to treat HNC could potentially improve outcomes. There is currently no drug approved in the adjuvant and neoadjuvant settings in the head and neck cancer market, making this a lucrative target for pharmaceutical companies.

Although there are not many trials looking into genetic changes, these mutations could be used as potential therapeutic targets, providing a unique opportunity in the head and neck cancer market for future personalized, targeted therapies.

However, some factors are responsible for the slow growth of the head and neck cancer market. The role of HPV in head and neck cancer is still debatable. It is believed that HPV cancer responds better in general, but mixed results have been observed with immunotherapy, so more clarity is still needed on this point. More curative options in the head and neck cancer market are required because current therapies only allow researchers to achieve a few months of survival.

Moreover, immunotherapy use is still unclear; some patients respond very well to it, while others do not. There is still no agreement on when to discontinue these treatments. The introduction of generics, the expiration of patent protection for various drugs, and increased healthcare costs are all major threats to the head and neck cancer market.

Furthermore, many drugs are being developed in China, and other countries are attempting to enter the global head and neck cancer market; the FDA recently rejected the BLA of a few drugs, emphasizing that all drugs should be evaluated across diverse patient populations and multiple countries. This will impact the approval of drugs in the head and neck market being researched in various countries.

 

Scope of the Head and Neck Cancer Market Report

• Therapeutic Assessment: Head and Neck Cancer current marketed and emerging therapies
• Head and Neck Cancer Market Dynamics: Head and Neck Cancer market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Head and Neck Cancer Market Access and Reimbursement

Discover more about drugs for head and neck cancer in development @Head and Neck Cancer Clinical Trials

Table of Contents

 

Related Reports

Head and Neck Cancer Epidemiology Forecast

Head and Neck Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the head and neck cancer epidemiology trends.

Head and Neck Cancer Pipeline

Head and Neck Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key head and neck cancer companies, including Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La Roche, among others.

Metastatic Head and Neck Cancer Pipeline 

Metastatic Head and Neck Cancer Pipeline Insight – 2022 report provide comprehensive insights into the pipeline landscape, including clinical and non-clinical stage products, and the key metastatic head and neck cancer companies, including Chia Tai-Tianqing, Kura Oncology, Hoffmann-La Roche, Eli Lilly, and Company, among others.

Recurrent or Metastatic Head and Neck Cancer Market

Recurrent or Metastatic Head and Neck Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key recurrent or metastatic head and neck cancer companies, including Eisai, Merck AbbVie, among others.

Recurrent or Metastatic Head and Neck Cancer Pipeline

Recurrent or Metastatic Head and Neck Cancer Pipeline Insight – 2022 report provides comprehensive insights into the pipeline landscape, including clinical and non-clinical stage products, and the key recurrent or metastatic head and neck cancer companies, including Eisai, Merck AbbVie, among others.

HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline

HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key HPV+ recurrent/metastatic head and neck cancer companies, including BioNTech, Cue Biopharma, Hookipa Pharma, among others.

Other Trending Reports

Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | CAR-T Pipeline Insight | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Outlook Report | Crows Feet Market Insight | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market

Browse through our latest blog to get more insights on the Head and Neck Cancer Treatment Landscape

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187  
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/head-and-neck-cancer-market-to-surge-at-a-cagr-of-5-1-by-2032--delveinsight-301633829.html

SOURCE DelveInsight Business Research LLP